Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00142883 · ClinicalTrials.gov registry record · NA
The Effects of GABA Enhancing Medications on Individuals Addicted to Cocaine - 3
A NA study, sponsored by Yale University.
- Terminated
- Registry status
- NA
- Development phase
- 72
- Enrollment target
NCT00142883 is a NA study that was terminated before completion, run by Yale University. The registered enrollment target is 72 participants.
The verdict
NCT00142883, a NA study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- NA
- Development phase
- 72 participants
- Enrollment target
Study Summary
Gamma-aminobutyric acid (GABA) is a type of neurotransmitter, which is a chemical that transmits information within and from the brain to all parts of the body. By lowering the level of another neurotransmitter called dopamine, GABA may have the ability to diminish cocaine cravings in addicts. The purpose of this study is to gather information on the interaction between cocaine and selected GABA enhancing medications in individuals addicted to cocaine. This may lead to future clinical studies using GABA medications to treat cocaine addiction.
Interventions
- DRUG placebo
- DRUG Pregabalin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2004-09 |
| Est. Completion | 2006-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00142883
The ClinicalTrials.gov registry entry for NCT00142883 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00142883 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00142883 about?
NCT00142883 is a clinical study titled "The Effects of GABA Enhancing Medications on Individuals Addicted to Cocaine - 3". Gamma-aminobutyric acid (GABA) is a type of neurotransmitter, which is a chemical that transmits information within and from the brain to all parts of the body. By lowering the level of another neurotransmitter called dopamine, GABA may have the ability to diminish cocaine cravings in addicts. The p...
What is the current status of trial NCT00142883?
This trial is currently terminated. It is a NA study. The enrollment target is 72 participants. The study started on 2004-09. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00142883?
The interventions under investigation include: placebo (DRUG), Pregabalin (DRUG).
Who is sponsoring clinical trial NCT00142883?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.